Opinion of the Transparency Council – prednisone
At its meeting on 9 June 2025, the Transparency Council adopted opinion No. 104/2025 on the inclusion of medicines containing the active substance prednisone in the scope of indications for use or dosage, or method of administration other than those specified in the Summary of Product Characteristics